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Long term outcome after coronary stent
implantation: a 10 year single centre experience of
1000 patients
R T van Domburg, D P Foley, P P T de Jaegere, P de Feyter, M van den Brand,
W van der Giessen, J Hamburger, P W Serruys
Abstract
Objective—To describe the long term
clinical outcome (up to 11 years) after
coronary stenting.
Design—A single centre observational
study encompassing 1000 consecutive pa-
tients with a first stent implantation (1560
stents) between 1986 and 1996, who were
followed for at least one year with a
median follow up of 29 months (range
12–132 months).
Results—Up to July 1997 the cumulative
incidence of the major adverse cardiac
events (MACE) of death, non-fatal acute
myocardial infarction, coronary artery
bypass grafting, and repeat percutaneous
transluminal coronary angioplasty was
8.2%, 12.8%, 13.1%, and 22.4%, respec-
tively. Survival at one, three, and five
years was 95%, 91%, and 86%, respec-
tively. Comparison of MACE incidence
during the “anticoagulant era” and the
“ticlopidine era” revealed significantly
improved event free survival with ticlopi-
dine (27% v 13%; p < 0.005).Multivariable
analyses showed that ejection fraction
< 50% (relative risk (RR) 4.1), multivessel
disease (RR 3.0), diabetes (RR 2.9), im-
plantation in saphenous vein graft (RR
2.1), indication for unstable angina (RR
1.9), and female sex (RR 1.7) were inde-
pendent predictors of increased mortality
after stenting. Independent predictors of
any MACE were multivessel stenting (RR
2.0), implantation in saphenous bypass
graft (RR 1.6), diabetes (RR 1.5), antico-
agulant treatment (versus ticlopidine and
aspirin) (RR 1.5), bailout stenting (RR
1.5), multivessel disease (RR 1.4), and
multiple stent implantation (RR 1.5).
Conclusions—Long term survival and inf-
arct free survival was good, particularly in
non-diabetic men with single vessel dis-
ease and good ventricular function, who
had a single stent implanted in a native
coronary artery. A dramatic improve-
ment was observed in event free survival,
both early and late, with the replacement
of anticoagulation by ticlopidine. This, of
course, cannot be separated from im-
proved stent implantation techniques be-
tween 1986 and 1995. Ultimately, almost
40% of the patients experienced an ad-
verse cardiac event (mainly repeat inter-
vention) in the long term.New advances in
restenosis treatments and in secondary
prevention must be directed at this aspect
of patient management after stenting.
(Heart 1999;82(supplement II):II27–II34)
Keywords: stents; percutaneous transluminal coronary
angioplasty; follow up; predictors; survival; registry
The widely heralded results of two simultane-
ously completed randomised trials,1 2 showing
apparently superior angiographic or clinical
outcomes, or both, with stenting in selected
patients, in comparison with balloon angio-
plasty, has led to widespread use of coronary
stenting for diverse indications. Although one
year and three year follow up studies have sug-
gested sustained benefit of stenting,3–13 long
term follow up studies of large patient groups
have not yet been reported.
To obtain more insights into this aspect of
stenting, we investigated the occurrence of
major adverse cardiac events up to 11 years
after stenting in 1000 patients consecutively
treated at a single centre between 1986 and
1996. We also investigated the influence of the
change from anticoagulation to antiplatelet
treatment on long term outcome and predic-
tors of major adverse cardiac events (MACE).
Methods
STUDY PATIENTS
From November 1986 through August 1996,
1000 consecutive patients underwent a first
stent implantation. During the follow up
period, 46 patients underwent a further
separate stent procedure, three patients under-
went two additional stent procedures, and one
patient underwent four stent procedures. Two
or more stents were implanted in 352 patients.
Stents were implanted across lesions in saphe-
nous vein grafts in 126 patients. Full systematic
anticoagulation treatment was used in 443
patients (from 1986 to July 1995) and
antiplatelet treatment in 553 patients. Most
patients (n = 625) received a stent electively.
All patients gave informed consent according
to the principles of the Declaration of Helsinki
and use of new stents was always approved by
the medical ethics committee.
STENT IMPLANTATION PROCEDURE
Angioplasty was performed using mainly 8
French gauge catheters via the femoral route.
Heparin 10 000 iu was administered parentally
in addition to 250 mg aspirin at the beginning
of the procedure; thereafter activated coagula-
tion time was measured hourly and additional
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5000 iu heparin given to maintain the activated
coagulation time above 300 seconds. All
patients were pretreated with aspirin. For
planned stent implantation up until the early
months of 1995, dextran 500 ml was given
intravenously over two hours, beginning before
the procedure; for unplanned implantations
dextran administration was initiated during the
procedure. Also, during that period, intra-
venous heparin infusion was continued after
the procedure until coumadin, administered
following the procedure, reached therapeutic
concentrations. Coumadin was then continued
for three months. From 1995 onward, the use
of periprocedural dextran and postprocedural
heparin and coumadin was discontinued, and
ticlopidine 500 mg per day was started imme-
diately after the procedure or, in the case of
elective implantations, during the 24 hours
before the procedure where possible and
continued for four weeks (2 × 250 mg per day).
Intracoronary glyceryl trinitrate was generally
used before all contrast injections intended for
online or oZine quantitative coronary angio-
graphy (QCA) analysis, and additionally to
treat coronary spasm where necessary. In the
case of bypass graft stenting and sometimes for
stenting during acute myocardial infarction,
intragraft (or intracoronary) verapamil was
often administered in the context of poor run-
oV or “no reflow”, considered generally
because of microembolisation. The use of
abciximab before or during coronary angio-
plasty in selected patients with unstable angina
or high risk candidates was started in mid-1995
and was used according to existing protocols.
In general, monorail dilatation balloon cath-
eters were used for balloon angioplasty, thus
guidewires of 175 cm were usually employed.
Where over the wire stent delivery systems
were required (such as the Palmaz-Schatz, the
first generation ACS Multilink, and the Wall-
stent) a 175 cm wire was replaced by a 300 cm
or longer wire. The vast majority of stents used
during the described study period were hand
crimped on the monorail balloon used for
lesion dilatation. In the case of elective stent
placement, adequate but not aggressive pre-
dilatation was generally performed using a bal-
loon matched 1:1 to the reference vessel diam-
eter (measured routinely by online quantitative
angiography using the coronary angiography
analysis system), to facilitate stent placement
and avoid the risk of unnecessary dissection. In
the case of unplanned or emergency stenting,
after failed balloon angioplasty, the most tech-
nically suitable stent available that could
resolve the problem in the safest and most eY-
cient manner was chosen. Thus the length of
segment to be covered, the diameter of the ves-
sel, and the presence of unfavourable morpho-
logical circumstances were taken into consid-
eration, as well as the known technical
characteristics of the available stents, in the
usual way. Before the emergence of the
importance of truly “optimal” stent deploy-
ment, using a motto of high pressure postdila-
tation with oversized balloons, in late 1994,
post dilatation after stent deployment was only
performed if the angiographic result after
deployment was unsatisfactory, based on on-
line QCA analysis. Generally the appearance of
a “step up/step down” in the stented area was
considered satisfactory, and in the absence of
that, a diameter stenosis < 30% by online QCA
analysis, with a minimum of two views.
Reference to the “anticoagulant era ” and
“ticlopidine era” is a means of identifying the
change in adjunctive pharmacotherapy as well
as the virtually simultaneous application of the
concept of optimal stent placement. The iden-
tifiable diVerence could perhaps equally be
described in terms of “early stenting practice”
and “modern stenting practice”.
DATA COLLECTION AND FOLLOW UP
All patients were followed for at least one year
post stenting with a median follow up of 29
months. Clinical follow up data were obtained
by a combination of review of hospital records
for patients who continue to be followed at this
institution, and by enquiry to referring cardi-
ologists within the referral area and question-
naires sent to general practitioners. Attention
was focused on the occurrence of the hard
MACE of death, myocardial infarction, coron-
ary artery bypass surgery (CABG), and repeat
percutaneous transluminal coronary angio-
plasty (PTCA).14 The diagnosis of myocardial
infarction was based upon: an episode of
prolonged typical ischaemic pain > 30 minutes
unrelieved by vasodilation treatment; a typical
serum enzyme pattern; and the development of
new pathological Q waves in two or more con-
tiguous ECG leads. All revascularisations were
categorised according to whether they involved
the target lesion, target vessel, or non-target
vessel. Complete clinical follow up was ob-
tained in 990 (99%) patients. In 10 patients
who had moved abroad, survival status could
not be retrieved and the last available follow up
data were used, obtained at 1–52 months after
stenting.
For the purpose of examining predictors of
long term outcome in multivariable analyses,
the following characteristics were selected as
being of relevance: age; sex; diabetes; hyper-
tension; cholesterol; smoking; prior myocardial
infarction; prior CABG; prior PTCA; extent of
coronary disease; left ventricular function;
elective or bailout implantation; indication
for unstable angina; post treatment withFigure 1 Yearly incidence of stent implantations compared to all angioplasty procedures.
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anticoagulation or antiplatelet drugs; multives-
sel stenting; type of stent; use of multiple
stents; total length of stent(s) implanted; stent
size < 3 mm; stenting in native coronary vessel
or saphenous vein graft vessel and at the native
coronary target vessel (left anterior descending
coronary artery versus right coronary artery
versus left circumflex coronary artery).
STATISTICAL ANALYSIS
Survival and event free survival were estimated
by Kaplan-Meier curves. Among patient
subgroups—for example, native versus bypass,
anticoagulation versus ticlopidine—the log
rank test was used to compare survival curves.
Data are expressed as mean (SD). Continuous
variables were compared by Student’s t test,
and categorical variables by ÷2 tests. The inde-
pendent association of the clinical characteris-
tics with long term mortality, mortality or
infarction, and any major cardiac event was
tested by using the Cox proportional hazard
model. Logistic regression was used for the
in-hospital outcome.
Results
The study cohort comprised 1000 patients
with a first stent implantation, who underwent
placement of 1560 stents (mean 1.6 stents per
patient) in 1063 vessels. Multivessel stenting
was performed in 60 patients (6%). Median
follow up was 29 months with a range of
12–132 months. The target vessels were the left
anterior descending coronary artery (44%),
left circumflex coronary artery (16%), right
coronary artery (28%), left main coronary
artery (< 1% (seven patients)), and saphenous
vein grafts (11%). Evolution of stent implanta-
tion practice over the years is shown in fig 1.
Baseline characteristics are shown in tables 1
and 2. Mean age was 59 years (range 28–86
years) and 73% of the patients were male. The
indication for PTCA was unstable angina in
41% and acute myocardial infarction in 6%.
Diabetes mellitus was present in 97 patients
(10%). Three hundred and ninety one patients
(39%) had a prior myocardial infarction.
Previous CABG had been performed in 160
patients (16%) and prior PTCA in 247 patients
(25%). Most patients (54%) had one vessel
disease. Bailout stenting (acute or threatened
vessel closure) occurred in 27% of the patients.
The majority of the stents used were Palmaz-
Schatz (32%), Wallstent (24%), NIR stent
(18%), and AVE stent (8%). A total of 10 other
stent types were used in the remaining 18%.
Saphenous vein graft stenting was predomi-
nantly performed using the Wallstent (82%).
The mean length of implanted stents was
32.7 (19) mm and the maximal balloon diam-
eter used after stenting was 3.6 (0.8) mm.
Table 3 outlines the clinical outcomes
in-hospital and long term. Fifteen patients died
during the periprocedural in-hospital period
(three patients indicated for acute myocardial
Table 1 Baseline clinical characteristics of patients
n (%)
Number of patients 1000
Vessels treated 1063
Age (range) (years) 59 (28-86)
Male 732 (73)
Diabetes 97 (10)
Hypertension 266 (27)
Smoking 256 (26)
Hypercholesterolaemia 281 (28)
History of MI 391 (39)
History of CABG 160 (16)
History of PTCA 247 (25)
Indication
Stable angina 500 (50)
Unstable angina 389 (39)
Acute MI 53 (5)
Unknown 58 (6)
Function class (CCS)
I 8 (1)
II 154 (26)
III 324 (56)
IV 98 (17)
Number of diseased vessels
1 vessel disease 535 (54)
2 vessel disease 261 (26)
3 vessel disease 178 (18)
Unknown 26 (3)
Ventricular function
Good (> 50%) 753 (76)
Moderate (30%–50%) 95 (10)
Poor (< 30%) 31(3)
Unknown 121 (12)
Target vessel
LAD 468 (44)
LCX 173 (16)
RCA 295 (28)
Left main 7 (1)
Saphenous bypass graft 120 (11)
Indication
Elective 625 (63)
Bailout 375 (37)
Angiographic success 948 (95)
Clinical success* 858 (86)
*Freedom from death, myocardial infarction, CABG or repeat
PTCA.
CCS, Canadian Cardiovascular Society; LAD, left anterior
descending coronary artery; LCX, left circumflex coronary
artery; MI, myocardial infarction; RCA, right coronary artery.
Table 2 Stent characteristics
Stent length (mm) (mean (SD)) 32.7 (19)
Balloon size (mm) (mean (SD)) 3.6 (0.8)
Number of implanted stents (mean (SD)) 1.6 (0.9)
Multivessel stenting (n) 58 (5.8%)
Target vessel LAD LCX RCA Left main SVG Total
Type of stent (n (%))
Palmaz-Schatz* 288 (41) 76 (32) 107 (24) 2 (33) 20 (12) 493 (32)
Wall stent† 82 (12) 28 (12) 129 (29) 0 (0) 139 (82) 378 (24)
NIR‡ 160 (23) 51 (22) 69 (15) 2 (33) 6(4) 288 (18)
AVE§ 47 (7) 20 (9) 47 (11) 0 (0) 3 (2) 117 (8)
Other stent types¶ 125 (18) 60 (26) 95 (6) 2 (33) 2 (1) 284 (18)
*Cordis, Johnson & Johnson Interventional Systems; †Schneider Europe; ‡Medinol Boston Scientific Corp; §Arterial Vascular
Engineering.
¶Other stent types used were ACS Multilink Guidant (n = 63), Bestent Medtronic (n = 58), Gianturco-Roubin Cook (n = 63),
Cordis (n = 43), Wiktor Medtronic (n = 26), Radius Scimed Boston Scientific Corp (n = 9), Crown Johnson & Johnson Interven-
tional Systems (n = 9), ACT-one Progressive Angioplasty Systems Inc (n = 6), and Freedom Global Therapeutics (n = 5).
LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; SVG, saphenous
bypass graft.
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infarction, seven patients for unstable angina,
and five patients for stable angina), yielding a
mortality of 1.5%. Forty nine patients (4.9%)
underwent a CABG during the same hospitali-
sation, of which 21 were truly emergent
(directly from the catheterisation laboratory).
From 1994 to 1996 this incidence fluctuated
around 1.3% per year (fig 2). Fifty five patients
(5.5%) underwent repeat angioplasty during
the same hospital admission (35 patients in the
anticoagulant era and 18 patients in the
ticlopidine era). Acute myocardial infarcts
occurred in 68 patients (6.8%) and subacute
thrombosis occurred in 30 patients (16 patients
in the anticoagulant era and 14 patients in the
ticlopidine era). Major bleeding complications
occurred in 36 patients necessitating blood
transfusion (3.6%) or vascular surgery (2.7%).
The median hospital stay for the whole study
population was four days. Our study group
included 53 patients (5%) who underwent a
stent implantation for evolving acute myocar-
dial infarction and 52 patients (5%) in whom
the procedure was an angiographic failure.
During the 11 year late follow up a total of 67
patients (6.7%) died, 60 patients (6%) had a
myocardial infarction, 82 patients (8%) under-
went CABG, and a repeat angioplasty proce-
dure was performed in 171 patients (17%). Of
the 50 patients (5%) who underwent a repeat
stent implantation, in 30 they were performed
in the same vessel.
Routine follow up angiography was per-
formed in 630 patients (63%). At baseline sig-
nificant one vessel disease had been reported in
477 of these patients (76%), and this was
decreased to 251 patients (40%) at follow up;
250 patients (40%) had no significant coronary
lesions at follow up. An increase in vessel
disease was reported in 12% of patients at fol-
low up. Of the total of 303 patients who under-
went any repeat revascularisation after the
index procedure, a target lesion revascularisa-
tion was performed in 198 patients (65%) and
a target vessel revascularisation was performed
in a further 96 patients (32%). Eighty five
patients (28%) underwent revascularisation in
a new vessel.
Survival and event free survival (freedom
from death, myocardial infarction, and revas-
cularisation) curves are shown in fig 3. By
Kaplan-Meier estimates, at six months, one
year, three years, and five years the cumulative
survival rates were 97%, 95%, 91%, and 86%,
respectively, and the associated event free
survival rates were 72%, 63%, 55%, and 48%,
respectively.
Multivariable analysis could be performed in
876 patients with complete data. Independent
predictors of mortality (table 4) were ejection
fraction < 50% (relative risk (RR) 4.1),
diabetes (RR 2.9), multivessel disease (RR
3.0), unstable angina (RR 1.9), saphenous vein
graft implantation (RR 2.1), and female sex
(RR 1.73). Ejection fraction (RR 2.3), multi-
vessel disease (RR 1.5), use of anticoagulants
(versus ticlopidine and aspirin) (RR 2.0),
unstable angina (RR 1.4), and diabetes (RR
1.6) were independent predictors of death or
myocardial infarction. Predictors of any
MACE were multivessel stenting (RR 2.0),
implantation in saphenous bypass graft (RR
1.6), diabetes (RR 1.5), anticoagulant treat-
ment (versus ticlopidine and aspirin) (RR 1.5),
bailout stenting (RR 1.5), multivessel disease
(RR 1.4), and multiple stent implantation (RR
1.4). Predictors of early occurrence of a major
cardiac event were use of anticoagulants (RR
3.1), bailout stenting (RR 2.5), use of the larg-
est balloon diameter < 3 mm (RR 2.5), and
multiple stent implantation (RR 1.5). Use of
anticoagulants (RR 1.4), diabetes (RR 2.0),
multivessel disease (RR 1.5), bypass graft
stenting (RR 1.5), use of multiple stents (RR
1.9), and prior intervention (RR 1.5) were pre-
dictors of a late event (> 6 months). The type
of stent was of no predictive value of mortality
or any MACE.
Figure 4 shows significantly better survival
for native coronary artery stenting versus
Table 3 Major cardiac events in 1000 patients
In-hospital Out-hospital Total
All* Ranking† All* Ranking† All* Ranking†
Death 15 15 67 67 82 82
MI 68 66 60 46 128 104
CABG 49 35 82 63 131 87
Repeat PTCA 55 26 171 110 224 114
Subacute thrombosis 30
*All, all events non-mutually exclusive analysis; †Ranking, frequency of events in descending order
of severity (death worst outcome, followed in order of ranking by acute myocardial infarction,
bypass surgery, repeat intervention).
Figure 2 Yearly incidence of true emergency CABG after stent procedure.
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saphenous vein grafting (96% v 92% at one
year (p = 0.3) and 92% v 67% at five years
(p < 0.0001)). Event free survival was 69% v
49% at one year (p < 0.001) and 57% v 25% at
five years (p < 0.0001)).
Detailed data on symptomatic status and the
use of medication as of July 1997 were available
in 679 (68%) patients. Sixty seven per cent
were in Canadian Cardiovascular Society
(CCS) class 0 or I, 16% were in class II, 13%
were in class III, and 4% were in class IV. Sev-
enty one per cent of the patients were taking
aspirin, 49% were using â blockers, 31% were
taking calcium antagonists, and 19% were
using nitrates. Anticoagulant treatment was
being used in 9% of the patients, 18% were
taking angiotensin converting enzyme inhibi-
tors, and one third of the patients were using
cholesterol lowering agents.
ANTICOAGULANT COMPARED WITH ANTIPLATELET
TREATMENT
Up to July 1995, 443 patients had been treated
with conventional anticoagulation; between
then and August 1996, 553 patients received
ticlopidine and aspirin. Ticlopidine was with-
drawn because of severe leucopenia in 0.2% of
patients. To adjust for diVerences in follow up
duration, follow up was truncated to two years.
DiVerences were found in the baseline charac-
teristics between the two groups. Age was simi-
lar, but in the ticlopidine group more patients
had diabetes (11% v 9%, p = 0.02), more had
prior myocardial infarction (44% v 37%), and
more were taking antianginal medications (â
blockers 58% v 39%, nitrates 21% v 16%, cal-
cium antagonists 33% v 28%). On the other
hand fewer patients in the ticlopidine group
were smoking (22% v 30%), and fewer ticlopi-
dine patients had prior revascularisation (33%
v 56%). Median hospital stay was seven days
(anticoagulants) versus three days (ticlopi-
dine). In the ticlopidine group more stents
were implanted per procedure (1.6 v 1.4),
fewer saphenous vein grafts were stented (6% v
19%), and stent procedures were more fre-
quently elective (75% v 50%). During the
in-hospital period MACE occurred in 24.1%
in the anticoagulation group and in 9.0% in the
ticlopidine group, with similar mortality (table
5). However, acute myocardial infarction
occurred more often in the anticoagulation
group (39 (9%) v 15 (3%) patients,
p < 0.0001). Emergency coronary bypass was
less frequent in the ticlopidine group (1.3% v
5.5%, p < 0.001) and early repeat angioplasty
was also lower in the ticlopidine group
(4% v 8%, p < 0.01). Bleeding and vascular
Table 4 Multivariable analysis: independent predictors of mortality, mortality and myocardial infarction, and any MACE
In-hospital Out-hospital All
RR 95% CI RR 95% CI RR 95% CI
Mortality
Diabetes – – 2.96 1.56 to 5.71 2.85 1.56 to 5.20
Ejection fraction < 50% 7.53 1.97 to 28.8 4.02 2.23 to 6.79 4.05 2.39 to 6.86
Multivessel disease – – 3.03 1.29 to 6.07 2.95 1.42 to 6.13
Bypass graft – – 2.06 1.23 to 4.21 2.09 1.16 to 3.74
Females 5.29 1.29 to 21.6 – – 1.73 1.01 to 2.94
Unstable angina – – 2.14 1.22 to 3.76 1.88 1.11 to 3.20
Mortality/myocardial infarction
Diabetes – – 1.81 1.09 to 3.29 1.64 1.05 to 2.56
Ejection fraction < 50% – – 3.01 1.95 to 4.65 2.33 1.61 to 3.35
Multivessel disease – – 1.64 1.00 to 2.71 1.52 1.08 to 2.13
Bypass graft – – 2.34 1.45 to 3.80 – –
Anticoagulation 2.59 1.47 to 4.56 – – 1.98 1.38 to 2.86
Bailout stenting 2.28 1.31 to 3.96 – – – –
Unstable angina – – – – 1.41 1.02 to 1.96
Diameter < 3 mm 2.52 1.17 to 5.43 – – – –
Multiple stents 1.75 1.03 to 2.98 – – – –
Any MACE
Diabetes – – 1.98 1.41 to 2.79 1.51 1.11 to 2.07
Prior intervention – – 1.52 1.13 to 2.64 – –
Ejection fraction < 50% – – – – – –
Multivessel disease – – 1.47 1.10 to 1.97 1.44 1.12 to 1.84
Bypass graft – – 1.46 1.00 to 2.14 1.62 1.17 to 2.23
Anticoagulation 3.07 1.91 to 4.94 1.41 1.07 to 1.86 1.50 1.17 to 1.92
Bailout stenting 2.54 1.63 to 3.94 – – 1.47 1.16 to 1.87
Multiple stents 1.55 1.01 to 2.39 1.86 1.43 to 2.42 1.38 1.38 to 2.16
Diameter balloon < 3 mm 2.55 1.33 to 4.89 – – – –
Multivessel stenting – – 1.91 1.00 to 3.65 2.02 1.09 to 3.73
Unstable angina 1.73 1.12 to 2.66 – – – –
MACE, mortality, myocardial infarction, CABG, and PTCA; RR, relative risk; CI, confidence interval.
Figure 4 Kaplan-Meier survival curves and event free survival curves (without death,
MI, CABG or repeat PTCA) in 880 native coronary grafts and in 120 saphenous bypass
grafts.
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complications necessitating blood transfusion
or vascular surgery were lower in the ticlopi-
dine group (1.7% v 6.2% (p < 0.001) and
0.6% v 5.7% (p < 0.0001), respectively). Mor-
tality after hospitalisation was similar; however,
more myocardial infarctions occurred during
late follow up in the anticoagulation group (9%
v 3%, p = 0.0001). Also the rate of late CABG
was lower in the ticlopidine group (6% v 9%,
p = 0.1), as was the rate for repeat PTCA (14%
v 23%, p < 0.001). Figure 5 shows the cumu-
lative survival rates, freedom from death or
myocardial infarction, and event free survival
of patients who were treated with anticoagula-
tion versus ticlopidine and aspirin.
Discussion
We have described the long term clinical
outcome of a heterogeneous patient population
undergoing stent implantation in an everyday
evolving practice at our centre and according to
the prevailing clinical practice between 1986
and 1996. This study cannot be compared to
clinical trials, which include only selected
patients and only contemporary techniques.
The major chronological milestones in evolv-
ing stent practice during this decade of coron-
ary stenting were: use of post dilatation to
improve acute results of Wallstent implantation
(1987); introduction of balloon expandable
Palmaz-Schatz stents (1991); appearance of
loose crimpable Palmaz-Schatz stents; gradual
replacement of anticoagulation by ticlopidine
and use of high pressure post dilatation with
“oversized” balloons (1994); and appearance
of multiplicity of stent designs (1995). The
principal observation which can be made on
the basis of our findings is that five year survival
after stent implantation in unselected “all
comers”, including the earliest experiences, is
an impressive 86%, which can be expected to
be even higher in the post ticlopidine and stent
optimisation era. Striking diVerences in the
occurrence of myocardial infarction and need
for CABG or repeat PTCA were found
between the patient groups treated with
anticoagulants and ticlopidine, both in-hospital
and late outcome. However, because of the
simultaneous evolution in stent implant tech-
niques with use of oversized balloons to high
pressure (> 14 atm), this apparent benefit of
ticlopidine treatment cannot be simply attrib-
uted to ticlopidine itself. The decrease in
Table 5 Relation of poststent antithrombotic treatment with occurrence of MACE in-hospital and over the long term*
In-hospital Long term
Anticoagulation Antiplatelets† p Value‡ Anticoagulation Antiplatelets† p Value‡
Number of patients 443 553 443 553
Death 6 (1.4) 7 (1.3) 21 (5.1) 23 (4.1)
Acute MI 39 (9.3) 15 (2.8) 0.0001 33 (8.7) 14 (2.7) 0.001
Repeat intervention
CABG 23 (5.5) 7 (1.3) 36 (8.6) 33 (6.2)
Angioplasty 33 (7.9) 19 (3.6) 0.0001 88 (22.9) 70 (13.6) 0.001
Complications
Bleeding 26 (6.2) 9 (1.7) 0.001
Vascular 24 (5.7) 3 (0.6) 0.0001
Values are n (%).
*Follow up in both groups truncated on two years; †Antiplatelets were ticlopidine, aspirin, or both; ‡Anticoagulation versus
antiplatelets.
Figure 5 Kaplan-Meier survival curves for death,MI, death or MI or CABG, and freedom from any MACE events in
436 patients treated with anticoagulation and in 522 patients treated with ticlopidine.
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bleeding complications can, however, be attrib-
uted to the cessation of systematic anticoagula-
tion.
PREDICTORS OF OUTCOME
The prognosis of non-diabetic patients with
single vessel disease and unimpaired ventricu-
lar function, who had a single stent implanted
in native arteries (n = 299), is excellent (95%
survival at five years). Poor left ventricular
function was associated with greater risk of
death in-hospital (RR 7.5) and late outcome
(RR 3.9). Women had five times higher risk of
in-hospital death than men, and two times
overall increased risk. Use of anticoagulants
was associated with double the risk of death or
myocardial infarction and also a 50% higher
risk of any MACE. Bypass graft stenting had
twice the increased risk of death than native
vessel stenting. Also implantation of multiple
stents in the same procedure was associated
with a higher risk of any MACE, as was stent-
ing in multiple vessels.
It is noteworthy from the Kaplan-Meier sur-
vival curves (fig 3) that the reintervention rate
in the second part of the first year after stent
implantation was still increasing. This finding
is relevant for clinical trials which reported
events at six months, and indicates that an
extended follow up of nine months or one year,
as is becoming standard practice, would be a
more honest appraisal of the intermediate inci-
dence of cardiac events related to restenosis.
Although stent implantation has been shown
to be as safe and eVective in diabetic patients as
in non-diabetics in the short term,15 our data
show diabetes to be an independent predictor
of reduced long term survival and event free
survival, in agreement with a recent three year
clinical follow up study of Palmaz-Schatz stent
implantation.6 These findings raise similar
issues to the recent revelations from the bypass
angioplasty revascularisation investigation
(BARI) trial16 and other studies17 of diabetics
with multivessel disease treated by balloon
angioplasty, although poorer outcome in dia-
betics in this study and indeed in general may
be more related to non-target lesion events in
the longer term because of progression of
disease.
The traditional risk factors, multivessel
disease and impaired left ventricular function
(ejection fraction < 50%), in agreement with
the findings frommost other previous stent and
angioplasty studies, are associated with signifi-
cantly reduced long term survival and survival
without cardiac events. However, advanced age
was not found to be associated with adverse
outcome; this indicates that older patients, who
are considered to be generally at increased risk
for angioplasty18 and bypass surgery
complications,19 may be eVectively treated by
stenting, especially with the reduced bleeding
risks with antiplatelet agents.
In-hospital outcome of stent implantation in
saphenous vein grafts is highly acceptable, but
long term outcome is poor, as we have
previously reported,20 although some investiga-
tors have described results similar to ours as
acceptable.21 Although stenting has been
shown to provide superior short term clinical
results compared with balloon angioplasty,22
this patient group continues to present a major
therapeutic challenge, apparently because of
the indolent nature of advanced coronary and
graft disease post CABG.
The increased risk of reinterventions after
implantation of multiple stents is in agreement
with findings from other studies23 24 generally
reporting an increased risk of angiographic
restenosis or clinical events, or both, after six
months’ follow up, associated with multiple
stent placement. However, one single centre
study has recently reported no increase in late
clinical events of contiguous placement of three
or more stents compared with placement of
one or two stents.25
Improved late outcome in the “ticlopidine
era” (even after the six months “restenosis
window”) compared to the anticoagulation era
has not been previously reported. Although the
short term advantage of antiplatelet over
anticoagulant treatment has been well docu-
mented (with26 or without27 intravascular ultra-
sound guidance), especially in high risk
patients,28 no influence on six month angio-
graphic restenosis or target lesion reinterven-
tion could be detected in the intracoronary
stenting and antithrombotic regimen (ISAR)
randomised trial.29 Accordingly, evolving stent
implantation techniques during the study
period described here cannot be separated
from the changeover to ticlopidine and are
likely to be at least partly responsible for the
observed long term clinical benefit superficially
attributable to treatment with ticlopidine.
STUDY LIMITATIONS
This study has several important limitations. It
is an observational study of daily clinical prac-
tice with both prospective and retrospective
data collection during the first 11 years of stent
implantation, with many stent types used in
diverse clinical circumstances. The entire evo-
lution of stent practice over the past decade is
covered in this study and the patient group is
truly heterogeneous, so the results must be
interpreted with these considerations in mind.
CONCLUSIONS
Long term infarct free survival in our first 1000
patients who underwent stent implantation
according to the “best clinical practice of the
day” was eminently acceptable. Non-diabetic
patients with single vessel disease and normal
ventricular function, who had a single stent
implanted in a native coronary artery, had par-
ticularly good clinical outcome. There was a
dramatic improvement in event free survival,
both early and late, with the replacement of
anticoagulation by ticlopidine and the adop-
tion of more aggressive stent placement
strategies. Certain clinical predictors of in-
creased acute and late risk of adverse events
were identified, namely diabetes, multivessel
disease, saphenous vein graft stenting, and use
of multiple stents. Recent improvements in the
acute safety of interventions and possibly long
term clinical outcome thereafter, through
periprocedural use of platelet glycoprotein IIb/
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IIIa receptor antagonists,30 potential advances
in restenosis treatments (for example,
brachytherapy,31 stent coating and seeding,32
and gene or DNA based treatments33), and
secondary prevention measures (such as oral
antiplatelet agents34 and statins35) may have
beneficial eVects, especially in these high risk
patients but also on a broad basis.
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